PLoS ONE · 2015 · 50 citations · 42 references
MedicineOncologyPharmacologyApoptosisCancer GeneticsMolecular OncologyApoptosis In CancerApoptosis ResistanceCancer Molecular PathologyMalignant NeoplasmsMolecular Tumor ProfilingOvarian CancerEndometrioid NeoplasmsEndometrioid Ovarian CarcinomaIntron-exon JunctionsLow-grade Serous CarcinomaOvarian Cancer TreatmentP21 RegulationP53 MutationTp53 Mutations
Epithelial ovarian cancer is a diverse molecular and clinical disease, yet standard treatment is the same for all subtypes. TP53 mutations represent a node of divergence in epithelial ovarian cancer histologic subtypes and may represent a therapeutic opportunity in subtypes expressing wild type, including most low-grade ovarian serous carcinomas, ovarian clear cell carcinomas and ovarian endometrioid carcinomas, which represent approximately 25% of all epithelial ovarian cancer. We therefore sought to investigate Nutlin-3a--a therapeutic which inhibits MDM2, activates wild-type p53, and induces apoptosis--as a therapeutic compound for TP53 wild-type ovarian carcinomas. Fifteen epithelial ovarian cancer cell lines of varying histologic subtypes were treated with Nutlin-3a with determination of IC50 values. Western Blot (WB) and quantitative real-time polymerase chain reaction (qRT-PCR) analyses quantified MDM2, p53, and p21 expression after Nutlin-3a treatment. DNA from 15 cell lines was then sequenced for TP53 mutations in exons 2-11 including intron-exon boundaries. Responses to Nutlin-3a were dependent upon TP53 mutation status. By qRT-PCR and WB, levels of MDM2 and p21 were upregulated in wild-type TP53 sensitive cell lines, and p21 induction was reduced or absent in mutant cell lines. Annexin V assays demonstrated apoptosis in sensitive cell lines treated with Nutlin-3a. Thus, Nutlin-3a could be a potential therapeutic agent for ovarian carcinomas expressing wild-type TP53 and warrants further investigation.
42
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations
Medicine, Oncology, Pharmacology +15
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Peter Y. Park, Teresa A. Goldin, John C. S. Chang et al. · Case Reports in Oncology · 2015 · 5.3K citations · Full text
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15